HCA
Earnings were fine. The mood? Less so.
HCA Healthcare turned in a pretty steady first quarter: revenue of $19.11 billion and adjusted EPS of $7.15 both landed right around Wall Street’s expectations. That’s the corporate version of a clean landing — not flashy, but nobody’s reaching for the emergency exit either.
Guidance stayed put, which matters
Management also held onto its 2026 guidance, pointing to earnings of $29.10 to $31.50 per share and sales of $76.5 billion to $80 billion. For investors, that’s the key part: HCA didn’t flinch, even if the environment sounded “dynamic,” which is CEO-speak for “yeah, there’s some stuff going on.”
The Street took a small step back
Then came the analyst scribbles in the margins:
- Truist kept a Buy but trimmed its target to $535 from $546
- Oppenheimer stayed Outperform and cut to $520 from $540
- KeyBanc kept Overweight and lowered to $510 from $550
- Stephens also kept Overweight and pulled its target to $530 from $560
None of that screams panic. But when multiple firms shave targets right after earnings, it usually means expectations got nudged a little lower — even if the business itself is still humming.
Why investors should care
HCA shares popped 2.2% to $442 on Monday, so the market didn’t exactly throw a fit. But price targets are like the Street’s collective mood ring, and this one is flashing a slightly cooler shade of green.
Big picture: HCA’s business is still doing the thing investors want — growing, earning, and keeping guidance alive — but the easy upside may be getting a little harder to sell.